The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type
Lei Zhang(First Affiliated Hospital of Zhengzhou University), Mingzhi Zhang(Chinese Academy of Sciences), Chao Zhang(Hubei University of Medicine), Jia Sisi(First Affiliated Hospital of Zhengzhou University), Shanshan Fan(First Affiliated Hospital of Zhengzhou University), Jingyu Cao(First Affiliated Hospital of Zhengzhou University), Hong‐Wei Xue(South China Agricultural University), Liping Su, Feifei Nan(First Affiliated Hospital of Zhengzhou University), Zhaoming Li(First Affiliated Hospital of Zhengzhou University), Jinghua Wang(Beijing Tongren Hospital), Li Sucai(First Affiliated Hospital of Zhengzhou University)
Cited by 26
Related Papers
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250
miR-137 Is Frequently Down-Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42
|Digestive Diseases and Sciences|2011|140
miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
|Journal of Hematology & Oncology|2018|134